CD274 and neoplasm: A systematic review and meta-analysis support this, showing that overall response rates to immunotherapy were significantly higher in current and former smokers compared to never-smokers (36% vs. 26% vs. 14%; p = 0.02), with even greater differences among patients with PD-L1 tumor proportion score (TPS) ≥ 50% (current smokers 58% vs. never-smokers 19%; p = 0.03) [32].